Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• SPETIndependent statistical analysis of Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 8NCT03010423
• SPIRE-1An independent statistical analysis of SPIRE-1 (NCT01975376), the terminated phase 3 placebo-controlled trial of bococizumab for prevention of major cardiovascular events: stratified Cox hazard ratios, MMRM and ANCOVA lipid analyses, multiplicity and…Phase 3Results postedn = 16,784NCT01975376
• SPIRE-2Independent statistical analysis of SPIRE-2 (NCT01975389), the terminated phase 3 placebo-controlled trial of bococizumab in high-risk participants: stratified Cox hazard ratios for major cardiovascular events, MMRM and ANCOVA lipid analyses, and serious…Phase 3Results postedn = 10,564NCT01975389
• SPIRITIndependent statistical analysis of Antiarrhythmic Effects of Spironolactone in Patients With ICDs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04495712).Phase 4Results postedn = 90NCT04495712
• SPS3A detailed statistical review of SPS3, a randomized phase 3 trial of secondary prevention of small subcortical strokes, including its trial design, registered endpoints, planned statistical analysis, and interpretation.Phase 3n = 3,020NCT00059306
• SPTIndependent statistical analysis of Brain Biomarkers of Response to Treatment for Apraxia of Speech: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02046941).Phase NAResults postedn = 17NCT02046941
• Staged DEEPIndependent statistical analysis of Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01661205).Phase NAResults postedn = 30NCT01661205
• STANDUP AHFIndependent statistical analysis of Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 329NCT03016325
• STARDUSTIndependent statistical analysis of Liraglutide and Peripheral Artery Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04881110).Phase 4Results postedn = 60NCT04881110
• STEP-IPFIndependent statistical analysis of STEP-IPF (NCT00517933), a randomized phase 3 trial of sildenafil versus placebo in patients with pulmonary fibrosis and pulmonary hypertension, including endpoint definitions, reported statistical analyses, interpretation, and limitations.Phase 3Results postedn = 180NCT00517933
• STOPDAPT-2A statistical analysis of STOPDAPT-2, a randomized phase 4 trial comparing 1-month versus 12-month dual antiplatelet therapy in coronary artery disease, including its design, composite endpoint, planned analysis, and statistical interpretation.Phase 4n = 3,045NCT02619760
• STRENGTHIndependent statistical analysis of Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 13,078NCT02104817
• SUPPORTIndependent statistical analysis of A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 174NCT01874262
• SURPHIndependent statistical analysis of A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 64NCT03533244
• SURTAVIIndependent statistical analysis of SURTAVI, evaluating Medtronic CoreValve System TAVI versus surgical aortic valve replacement for severe symptomatic aortic stenosis, with emphasis on Bayesian non-inferiority methodology and the 24-month primary endpoint.Phase NAResults postedn = 1,746NCT01586910
• SWEDESIndependent statistical analysis of Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 205NCT00806403
• SWIFT DIRECTIndependent statistical analysis of SWIFT DIRECT (NCT03192332), a randomized trial comparing bridging thrombolysis with direct mechanical thrombectomy in acute ischemic stroke, including its design, modified Rankin Scale endpoint, planned analysis, and statistical…Phase NAn = 410NCT03192332
• Symplicity AFIndependent statistical analysis of Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 102NCT02064764
• SYMPLICITY HTN-3Independent statistical analysis of SYMPLICITY HTN-3, a randomized trial evaluating renal denervation with the Symplicity Catheter System in patients with uncontrolled hypertension. Includes trial design, endpoints, statistical methodology, and interpretation.Phase NAn = 535NCT01418261
• TALOS-AMIA statistical analysis of TALOS-AMI, a randomized phase 4 trial comparing aspirin plus ticagrelor versus aspirin plus clopidogrel in stabilized patients with acute myocardial infarction. Includes trial design, endpoints, planned statistical methods,…Phase 4n = 2,590NCT02018055
• TARDISIndependent statistical analysis of the TARDIS phase 3 trial evaluating triple antiplatelet therapy after ischaemic stroke, including design, endpoints, planned analysis, methodology, and interpretation.Phase 3n = 3,096NCT01661322
• TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).Phase NAResults postedn = 655NCT06020534
• TASTEA statistical analysis of the TASTE trial evaluating thrombus aspiration in patients with acute myocardial infarction, including trial design, endpoints, planned analysis, and statistical interpretation.Phase NAn = 7,243NCT01093404
• TAZPOWERIndependent statistical analysis of A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 12NCT03098797
• TEAM2Independent statistical analysis of Reducing Stroke Risk in African-American Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04402125).Phase NAResults postedn = 171NCT04402125
• TEMPO-2Complete statistical analysis of TEMPO-2, a randomized phase 3 trial of tenecteplase versus antiplatelet treatment for minor acute ischemic stroke with proven occlusion, including trial design, the 90-day modified Rankin Scale endpoint,…Phase 3Results postedn = 1,274NCT02398656
• TENSIONAn independent statistical analysis of TENSION (NCT03094715), a randomized trial of thrombectomy plus best medical care versus best medical care in acute stroke with extended lesion and extended time window.Phase NAn = 253NCT03094715
• TESIndependent statistical analysis of Electric Stimulation of the Eye to Improve Vision After Trauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02019927).Phase NAResults postedn = 97NCT02019927
• THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
• THRACEIndependent statistical analysis of THRACE (NCT01062698), a randomized trial evaluating intra-arterial thrombectomy in acute ischemic stroke, including design, endpoints, methodology, and statistical interpretation.Phase NAn = 412NCT01062698
• TIM-HF2Independent statistical analysis of TIM-HF2, a randomized phase 3 trial evaluating Remote Patient Management versus usual care in chronic heart failure. Includes trial design, endpoints, planned analysis, and statistical interpretation.Phase 3n = 1,571NCT01878630
• TINTINIndependent statistical analysis of Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 100NCT03347383
• TitAINIndependent statistical analysis of A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 52NCT03765788
• TNTIndependent statistical analysis of the TNT trial (NCT00327691), a randomized phase 4 study evaluating atorvastatin for cardiovascular risk reduction through intensive LDL lowering.Phase 4n = 8,600NCT00327691
• TOTALIndependent statistical analysis of the TOTAL trial (NCT01149044), evaluating routine aspiration thrombectomy with PCI versus PCI alone in patients with ST-segment elevation myocardial infarction undergoing primary PCI.Phase NAn = 10,732NCT01149044
• TRANSFORM-HFComplete statistical analysis of TRANSFORM-HF, the randomized phase 3 comparison of torsemide versus furosemide for management of heart failure, including time-to-event, rehospitalization, quality-of-life, and depression analyses.Phase 3Results postedn = 2,973NCT03296813
• TRILUMINATE PivotalIndependent statistical analysis of the TRILUMINATE Pivotal trial of the TriClip device in tricuspid regurgitation, including its hierarchical composite endpoint, win-ratio analysis, KCCQ, functional outcomes, safety, and statistical methodology.Phase NAResults postedn = 572NCT03904147
• TTRACKIndependent statistical analysis of Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 812NCT03842163
• TWO2DFUIndependent statistical analysis of Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 73NCT02326337
• UKPDSIndependent statistical analysis and educational interpretation of UKPDS (NCT01099865), evaluating high-sensitivity C-reactive protein and UKPDS Risk Score in type 2 diabetes.n = 56NCT01099865
• UNIVERSEIndependent statistical analysis of Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure: primary endpoint results, effect estimate…Phase 3Results postedn = 112NCT02846532
• V-EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 305NCT04545489
• VA CARDSIndependent statistical analysis of Coronary Artery Revascularization in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326196).Phase 4Results postedn = 198NCT00326196
• VALUEIndependent statistical analysis of the VALUE phase 3 trial comparing valsartan and amlodipine in essential hypertension, including trial design, the registered composite cardiac endpoint, planned statistical analysis, and interpretation.Phase 3n = 15,313NCT06395194
• VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…Phase 3Results postedn = 8,246NCT01986881
• VICARESIndependent statistical analysis of A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 19NCT03311269
• VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…Phase 3Results postedn = 5,050NCT02861534
• VICTORION-2PAn independent statistical analysis of VICTORION-2P, a randomized phase 3 trial evaluating inclisiran for prevention of cardiovascular events in participants with established atherosclerotic cardiovascular disease.Phase 3n = 17,004NCT05030428
• VICTORY-AFIndependent statistical analysis of Evaluation of the Phased Radio Frequency Ablation System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01693120).Phase NAResults postedn = 199NCT01693120
• VisipaqueIndependent statistical analysis of Comparison of Contrast Agents During CT Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534975).Phase NAResults postedn = 513NCT01534975

← All therapeutic areas